Field Orthopaedics

About Field Orthopaedics

Field Orthopaedics is an Australian medical device company founded in 2016 by engineer and then-CEO Dr. Chris Jeffery, alongside orthopaedic surgeons Dr. Greg Couzens and Dr. Libby Anderson. The company was established within the Australian medical community to develop solutions for shortcomings in surgical practices, specifically focusing on the underserved market of hand and wrist orthopaedics. This niche was identified due to a lack of investment and innovation compared to areas like hip and knee surgery.

The business operates by designing, manufacturing, and distributing orthopedic devices for the trauma and extremities markets, with a particular emphasis on hand surgery. Its business model is centered on a consultative approach, collaborating directly with surgeons to identify clinical problems and develop purpose-built products. The company generates revenue through the sale of its medical implant systems, which are distributed globally by Medartis AG, a Swiss-based company specializing in upper extremity healthcare. This strategic partnership allows Field Orthopaedics to leverage Medartis' global reach to expand its sales and distribution footprint.

Key products include the Field Micro Screw System, the NX Nail System, and the Griplasty™ CMC suspensionplasty device. The Micro Screw System, which received FDA approval in 2018, is designed for the fixation of small bone fragments in the hand, wrist, and foot, featuring cannulated titanium alloy screws that are smaller and provide stronger compression than many existing products. The NX Nail System is an intramedullary nailing system for treating extra-articular neck and shaft fractures in the hand through a minimally invasive technique. The company also offers a sterile, single-use version of the NX Nail to improve efficiency and reduce costs in surgical settings. In 2024, Field Orthopaedics received FDA clearance for its Griplasty™ system, a solution for basal thumb arthritis.

Since its inception, the company has achieved significant milestones, including securing multiple rounds of funding. By August 2024, it had closed a $20.8 million Series A financing round to support commercial expansion and the launch of new products. Key investors include the Flannery Family Office (Ilwella), US-based Tynan family office, and Acorn Capital.